Gilead reports positive HIV PrEP data for lenacapavir
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
Gilead reports results from pivotal Phase 3 PURPOSE 2 trial
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
Le Lézard15h
NaoTrac Robot Pioneers Robotic Neurosurgery in Bolivia with Successful Brain Tumor Biopsies
On November 5, 2024, Bolivia marked a historic moment in neurosurgery at Hospital Arcoiris, where two successful brain tumor biopsy surgeries were conducted using NaoTrac, the world's first autonomous ...
Le Lézard20h
Experts Link Year-Long Oncology Data Backlogs to Impacts on Patient Care
at 06:50 Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow Gilead Sciences, Inc. today presented the first in-depth look at full results from ...
Working to End the HIV Epidemic Through Innovation, Equity, Collaboration & Choice
From Bettina Bauer, Vice President, US HIV Treatment and Prevention, Gilead Sciences In 2022, there were up to 1.2 million ...
The New York Times12h
New York Times - Top Stories
At Mar-a-Lago, ‘Uncle’ Elon Musk Puts His Imprint on the Trump Transition He’s on the patio. He’s on the golf course. Everywhere President-elect Trump looks, there is the world’s richest ...